Published in J Clin Rheumatol on June 01, 2002
Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis (2003) 1.04
Treatment of catastrophic antiphospholipid syndrome. Curr Opin Rheumatol (2016) 0.88
Catastrophic antiphospholipid syndrome with severe acute thrombotic microangiopathy and hemorrhagic complications. Case Rep Med (2013) 0.82
Antiphospholipid syndrome presenting with acute digital ischaemia, avascular necrosis of the femoral head and superior mesenteric artery thrombus. BMJ Case Rep (2012) 0.75
Systemic lupus erythematosus and thrombosis. Thromb J (2015) 0.75
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum (2002) 5.12
Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) (2003) 4.00
International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis (2013) 3.99
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum (2002) 3.96
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum (2011) 3.81
Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA (2007) 2.91
Reversal of rivaroxaban-induced alterations on hemostasis by different coagulation factor concentrates – in vitro studies with steady and circulating human blood. Circ J (2014) 2.49
Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum (2013) 2.25
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis (2012) 2.21
Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med (2002) 2.17
Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis (2013) 2.11
Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis (2010) 2.09
Antineutrophil cytoplasmic antibodies. Lancet (2006) 2.06
[Bilateral suprarenal hematoma in a 46-year-old male]. Med Clin (Barc) (2008) 2.02
[Antiphospholipid syndrome: analysis of 27 patients]. Med Clin (Barc) (2013) 1.98
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum (2004) 1.89
Catastrophic antiphospholipid syndrome: where do we stand? Arthritis Rheum (2003) 1.79
Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther (2006) 1.78
Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am J Trop Med Hyg (2010) 1.77
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis (2012) 1.67
Sedation for cardioversion in the emergency department: analysis of effectiveness in four protocols. Ann Emerg Med (2003) 1.66
Immunotherapy for antineutrophil cytoplasmic antibody-associated vasculitis: challenging the therapeutic status quo? Trends Immunol (2008) 1.64
Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients. Medicine (Baltimore) (2003) 1.58
Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum (2006) 1.53
Vascular involvement in Behçet's disease. Isr Med Assoc J (2002) 1.53
Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology (Oxford) (2013) 1.46
Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine (Baltimore) (2005) 1.46
Lymphoplasmacytic lymphoma causing light chain cast nephropathy. Nephrol Dial Transplant (2012) 1.45
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis (2014) 1.45
Preventing death in the catastrophic antiphospholipid (Asherson) syndrome. Isr Med Assoc J (2007) 1.44
Triple association between hepatitis C virus infection, systemic autoimmune diseases, and B cell lymphoma. J Rheumatol (2004) 1.44
Efficacy of cyclophospamide in the treatment of interstitial lung disease associated with systemic sclerosis. Arch Bronconeumol (2011) 1.42
[Basic cardiopulmonary resuscitation program for high school students (PROCES). Results from the pilot program]. Med Clin (Barc) (2005) 1.42
Antiphospholipid syndrome in Mexican children. Isr Med Assoc J (2012) 1.39
Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore) (2002) 1.37
Targeting glutamine transport to suppress melanoma cell growth. Int J Cancer (2014) 1.21
Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics (2008) 1.20
Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore) (2006) 1.18
Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica (2002) 1.14
Sjögren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases. Medicine (Baltimore) (2005) 1.14
Immunosuppression and Chagas disease: a management challenge. PLoS Negl Trop Dis (2013) 1.12
Etiopathogenesis of Behcet's disease. Autoimmun Rev (2009) 1.11
Increased mortality in septic shock with the 4G/4G genotype of plasminogen activator inhibitor 1 in patients of white descent. Intensive Care Med (2007) 1.11
Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol (2015) 1.09
Synthesis of purine nucleosides built on a 3-oxabicyclo[3.2.0]heptane scaffold. J Org Chem (2011) 1.08
Antiphospholipid syndrome: frequency, main causes and risk factors of mortality. Nat Rev Rheumatol (2010) 1.08
Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore) (2004) 1.08
Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors. Semin Thromb Hemost (2008) 1.08
The prospects for designer single-stranded RNA-binding proteins. Nat Struct Mol Biol (2011) 1.07
Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, followup study. Arthritis Rheum (2005) 1.07
Adalimumab for the treatment of Behçet's disease: experience in 19 patients. Rheumatology (Oxford) (2012) 1.05
A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. Ann Rheum Dis (2010) 1.05
Effects of external and internal factors on emergency department overcrowding. Ann Emerg Med (2002) 1.04
Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev (2013) 1.04
Pathophysiology of Sjögren's syndrome. Arch Med Res (2006) 1.02
Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PLoS One (2013) 1.00
Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin Arthritis Rheum (2004) 1.00
Bi-stability of amplitude modulation AFM in air: deterministic and stochastic outcomes for imaging biomolecular systems. Nanotechnology (2010) 1.00
Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. Semin Arthritis Rheum (2008) 1.00
Factors influencing polyautoimmunity in systemic lupus erythematosus. Autoimmun Rev (2009) 0.99
Anti-glomerular basement membrane antibodies. Isr Med Assoc J (2014) 0.99
The overlap of Sjögren's syndrome with other systemic autoimmune diseases. Semin Arthritis Rheum (2006) 0.99
Catastrophic antiphospholipid syndrome and sepsis. A common link? J Rheumatol (2007) 0.99
Autoantibodies and prediction of reproductive failure. Am J Reprod Immunol (2006) 0.98
Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford) (2005) 0.98
Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases. Medicine (Baltimore) (2003) 0.97
Class III-IV proliferative lupus nephritis and pregnancy: a study of 42 cases. Am J Reprod Immunol (2005) 0.97
Towards advanced aqueous dye removal processes: a short review on the versatile role of activated carbon. J Environ Manage (2012) 0.96
Trends in illicit drug emergencies: the emerging role of gamma-hydroxybutyrate. J Toxicol Clin Toxicol (2002) 0.96
Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol (2004) 0.96
Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis (2011) 0.96
Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmun Rev (2011) 0.95
The multiple autoimmune syndromes. A clue for the autoimmune tautology. Clin Rev Allergy Immunol (2012) 0.95
Relapsing catastrophic antiphospholipid syndrome: report of three cases. Semin Arthritis Rheum (2007) 0.95
Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum (2006) 0.95
Therapeutic options in autoimmune myasthenia gravis. Autoimmun Rev (2007) 0.95